These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1076 related articles for article (PubMed ID: 11398914)

  • 1. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.
    Fenton C; Keating GM; Wagstaff AJ
    Drugs; 2004; 64(11):1231-61. PubMed ID: 15161329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
    Clemett D; Goa KL
    Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
    Eccleston C; Cooper TE; Fisher E; Anderson B; Wilkinson NM
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012537. PubMed ID: 28770976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial.
    Chang DJ; Desjardins PJ; Chen E; Polis AB; McAvoy M; Mockoviak SH; Geba GP
    Clin Ther; 2002 Apr; 24(4):490-503. PubMed ID: 12017395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical pharmacology of the selective COX-2 inhibitors].
    Burian M; Geisslinger G
    Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rofecoxib.
    Scott LJ; Lamb HM
    Drugs; 1999 Sep; 58(3):499-505; discussion 506-7. PubMed ID: 10493277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valdecoxib: a review.
    Chavez ML; DeKorte CJ
    Clin Ther; 2003 Mar; 25(3):817-51. PubMed ID: 12852704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
    Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
    Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoricoxib.
    Cochrane DJ; Jarvis B; Keating GM
    Drugs; 2002; 62(18):2637-51; discussion 2652-3. PubMed ID: 12466002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rofecoxib: clinical pharmacology and clinical experience.
    Weaver AL
    Clin Ther; 2001 Sep; 23(9):1323-38. PubMed ID: 11589252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.